445303-96-8

Upstream product

• 27996-87-8 2-fluoro-5-nitrobenzaldehye 
• 63878-71-7 2‐(difluoromethyl)‐1‐fluoro‐4‐nitrobenzene 

Downstream Products

• 1448529-64-3 2-(difluoromethyl)-1-fluoro-4-isothiocyanato-benzene 
• 1574312-05-2 C₁₇H₁₇F₃N₄O₂S 
• 1574312-11-0 1-[3-(difluoromethyl)-4-fluoro-phenyl]-3-[[5-(isopropylsulfamoyl)-2-pyridyl]methyl]thiourea 
• 1572514-70-5 C₁₈H₁₇F₃N₂O₄S 
• 1572516-61-0 5-chloro-3-[[3-(difluoromethyl)-4-fluorophenyl]carbamoyl]-2-fluorobenzene-1-sulfonyl chloride 
• 1572511-11-5 C₁₉H₁₉F₃N₂O₄S 
• 1572514-12-5 C₁₈H₁₆F₄N₂O₄S 
• 1572514-11-4 C₁₈H₁₅ClF₄N₂O₄S 
• 1572510-72-5 C₁₇H₁₇F₃N₂O₃S 

Relevant academic research and scientific papers

A kind of IDO inhibitor and use thereof

The embodiment of the invention provides general formula (I) compound or its pharmaceutically acceptable salts, stereoisomers, a tautomeric form each other, polymorphs, solvate, prodrug, metabolite or isotope derivatives, wherein the substituents R1

IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF

A compound as an indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, and an application thereof in the field of IDO1-related diseases, and in particular a compound as shown in formula (I) and a pharmaceutically acceptable salts thereof.

TRIAZOLES AS NR2B RECEPTOR INHIBITORS

Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B

This new pharmaceutical use (6-1, 6-dihydro-2-yl) amide derivative, as the inhibitor of this preparation and AKT (PKB) phosphoenzyme

The invention relates to the novel materials of formula (I), wherein each of the substituents R, R1, R2, R3, R4 and R5 is as defined herein. The materials are useful as inhibitors of AKT(PKB) phosphorylation.

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.